Skip to main content
Premium Trial:

Request an Annual Quote

Biotech Investment Highs

Last year was a good year for biotech with venture capital investment in the sector reaching $8.6 billion, and Technology Review's Mike Orcutt writes that 2015 could be good one as well.

Biotech, he notes, is second only to software for VC investment, and Greg Vlahos from PricewaterhouseCoopers tells him that the VC are gaining confidence in the life science sector as the research has matured.

Vlahos also says that there's been a surge in biotech IPOs, which also makes the field appealing to investors. Further, 2014 saw a number of so-called megadeals worth more than $100 million, which he tells Orcutt that the previous boom years of 2000 and 2007.

Filed under